Infinite Ties, a client advisory services education and training platform, launched a yearlong learning track designed for professionals working in CAS.
While many companies have not stated what they might do, last month’s tax legislation is helping ease some concerns while they grapple with tariff uncertainty.
Data has become one of the most valuable assets a company can own. Without data, AI systems would lack the foundation needed to learn, adapt, and generate meaningful insights.
Albert Bourla confirmed that he called President Donald Trump after receiving a letter asking Pfizer and a clutch of other pharmaceutical companies to lower drug prices or face consequences.
BMN 390 fell short of an immunogenicity threshold that BioMarin was looking for to support its further development. Employees working on the program have been redeployed within the company.
The number of biopharma professionals let go has increased year over year for three straight months. In July, nearly 8,000 people lost their jobs, due largely to Merck cutting roughly 6,000 employees. Sarepta Therapeutics and Moderna also announced significant workforce reductions.
Vertex reported healthy revenue in its second quarter earnings report, though news of VX-993’s mid-stage trial results and lack of alignment with the FDA regarding an expanded label for Journavx tempered analyst reactions, sending the stock down 13%.